• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

OXYBUTYNIN Drug Record

  • Summary
  • Interactions
  • Claims
  • OXYBUTYNIN chembl:CHEMBL1231 Approved

    Alternate Names:

    ANTUROL
    PROMICTULINE
    OXYTROL
    OXYBUTYNIN
    CONTIMIN 5
    KENTERA
    CYSTRIN
    DITROPAN XL
    DITROPAN
    LYRINEL XL
    URIMIN
    OXYTROL FOR WOMEN
    CONTIMIN 2.5

    Drug Info:

    Drug Class antispasmodics
    Year of Approval 1975
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications for treatment of overactive bladder
    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications for treatment of incontinence
    (1 More Sources)

    Publications:

    Sinha et al., 2010, AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder., Br. J. Pharmacol.
    Baldwin et al., 2009, Transdermal oxybutynin., Drugs
    Oki et al., 2007, Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder., J. Urol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Maruyama et al., 2006, Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder., J. Urol.
    Ito et al., 2009, Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice., Eur. J. Pharmacol.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Yarker YE et al., 1995, Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability., Drugs Aging
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Dmochowski, 2005, Improving the tolerability of anticholinergic agents in the treatment of overactive bladder., Drug Saf
    Nelson et al., 2006, Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor., J. Pharmacol. Exp. Ther.
  • OXYBUTYNIN   CHRM2

    Interaction Score: 2.18

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name AA-2010
    Novel drug target Established target
    Trial Name AP-1034,Anturol

    PMIDs:
    19446545 15963006 17222678 16188951 20590605 7620236


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXYBUTYNIN   CHRM3

    Interaction Score: 2.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Muscarinic acetylcholine receptor M3 antagonist
    Direct Interaction yes
    Trial Name transdermal oxybutynin patch, oxybutynin topical gel,Oxytrol, Kentera, Gelnique

    PMIDs:
    20590605 19275276 17222678 11752352 16406943 19446545 17016423 17139284 7620236


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXYBUTYNIN   CHRM1

    Interaction Score: 1.18

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name AA-2010
    Novel drug target Established target
    Trial Name AP-1034,Anturol

    PMIDs:
    20590605 17222678 17016423 17139284 16406943 7620236


    Sources:
    TdgClinicalTrial TEND

  • OXYBUTYNIN   CYP2D6

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • OXYBUTYNIN   CYP3A4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TEND: OXYBUTYNIN

    • Version: 01-August-2011

    Alternate Names:
    OXYBUTYNIN Primary Drug Name

    Drug Info:
    Year of Approval 1975
    Drug Class antispasmodics

    Publications:

  • TdgClinicalTrial: OXYBUTYNIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of incontinence
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • DTC: OXYBUTYNIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1231 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • ChemblDrugs: chembl:CHEMBL1231

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1231

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21